Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Luye Pharma Group ( (HK:2186) ) just unveiled an announcement.
Luye Pharma Group Ltd. announced the inclusion of five new products in China’s 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List, enhancing its market presence. This inclusion marks a significant milestone for the company, as it positions its products, such as Mimeixin® and Ruibailai®, for broader access and potential growth in the Chinese market, addressing critical needs in pain management and schizophrenia treatment.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development and commercialization of innovative drugs. The company operates in the healthcare industry, offering a range of pharmaceutical products, particularly in the areas of oncology, central nervous system disorders, and pain management.
YTD Price Performance: 38.71%
Average Trading Volume: 31,215,663
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.83B
See more data about 2186 stock on TipRanks’ Stock Analysis page.